High-dose chemotherapy and autologous bone marrow or In order to demonstrate the feasibility of mobilization, PBPC transplantation is an effective therapy for relapsed enrichment and engraftment of autologous peripheral and high risk non-Hodgkin's lymphoma (NHL) and blood CD34
9
/l (untransfused) in 15 (9-39) days. In order to of the effective methods also result in progenitor cell loss optimize the immunoaffinity column utilization we or damage which may delay hematopoietic engraftment.
14 stored the first PBPC collections overnight at 4؇C and A positive selection method using a CD34 + cell enrichment combined them with the next day's collection prior to procedure was shown to reduce the number of contaminatthe CD34 ؉ enrichment procedure in 11 patients. This ing breast cancer and myeloma cells in autologous marrow maneuver resulted in a significant decrease in the and PBPCs by 1-4 logs without compromising hematopo-CD34 ؉ cell recovery (resulting in reinfusion of a mean ietic engraftment. 15,16 CD34 + cells enriched from mobilized of 42% less CD34 ؉ cells). Although overnight storage PBPCs or BM have been shown to comprise the committed, did not affect neutrophil engraftment, platelet as well as the early, hematopoietic progenitor cells and engraftment was prolonged in this group of patients when reinfused after high-dose chemoradiation therapy even when Ͼ2.0 ؋ 10 6 CD34 ؉ cells/kg were re-infused. result in engraftment in patients who have breast cancer,
17
The overnight storage procedure should be further neuroblastoma, 18 small cell lung cancer, 19 multiple myeevaluated for its effects on the CD34 ؉ immunoaffinity loma 16 and NHL. 20 Peripheral blood count recovery after enrichment procedure, megakaryocyte progenitors and CD34 + cell transplantation has been shown to occur in a platelet engraftment. We conclude that CD34
؉ cells short time period, comparable to unenriched PBPC transenriched from peripheral blood result in rapid plantation.
engraftment after high-dose chemotherapy in patients
We investigated whether a sufficient number of CD34 + with advanced lymphoma that is comparable to that of hematopoietic progenitor cells that enable rapid hematopopatients receiving unenriched PBPCs.
ietic reconstitution could be collected and positively Keywords: peripheral blood CD34 + cell transplantation; enriched by the CD34 immunoaffinity column (CEPRATE CD34 + cell enrichment; lymphoma SC; CellPro, Bothell, WA, USA) from the peripheral blood of advanced lymphoma patients. Since lymphoma cells were shown not to express the CD34 surface marker 22 this Overnight storage serum direct bilirubin Ͻ2.0 mg/dl, and an actual or calculated creatinine clearance Ͼ60 ml/min. At the start of therIn order to reduce immunoaffinity column utilization and apy, a neutrophil count Ͼ1.2 × 10 9 /l and a platelet count the labor associated with cell processing, the first day leu-Ͼ100 × 10 9 /l were required. Patients were excluded if they kopheresis product from 11 patients was stored overnight had more than two prior chemotherapy regimens, prior pelat 4°C and combined with the next day leukopheresis vic radiation therapy or cumulative doxorubicin exposure product just prior to positive selection for CD34 + cells in excess of 500 mg/m 2 , major central nervous system dys-(overnight storage). If necessary subsequent collections function, active infection or a history of autoimmune diswere processed in the same fashion. This maneuver was ease. Patients were not excluded for evidence of tumor on adopted for the last consecutive 11 patients treated at the routine histologic staining of bilateral paraffin-embedded University Hospitals of Cleveland and resulted in 50% posterior iliac crest bone marrow biopsy specimens. reduction in column utilization and processing time. Thirty-two patients were registered between May 1995 and June 1996, and 21 proceeded with transplantation. Five patients were found to be ineligible after registration, four Clonogenic assay for committed hematopoietic patients had disease progression prior to PBPC collection progenitors or high-dose chemotherapy, one patient's transplant was delayed beyond allowed time due to an intercurrent infecUnseparated (1 × 10 5 /ml) and CD34 + enriched cells (0.3-tion and one patient withdrew from the study. The data 1.0 × 10 3 /ml) were grown in methylcellulose (Stem Cell from the study group were compared with that of a group Technologies, Vancouver, Canada) containing (final of NHL or HD patients (n = 35) who were treated at the concentration) 100 U/ml hIL-3 (Sandoz Research Institute, University Hospitals of Cleveland with the same high-dose Nutley, NJ, USA), 2 U/ml erythropoietin (Amgen, Thouchemotherapy protocol but were reinfused with unenriched sand Oaks, CA, USA), 100 U/ml GM-CSF (Immunex, PBPCs between January 1994 and June 1996.
Seattle, WA, USA) and 0.1 mM hemin (Sigma). 25 ing the entire CD45 positive (dim and bright) population. Background fluorescent activity determined by isotypic antibody was subtracted from each measurement.
Positive selection of CD34
+ cells from mobilized PBPCs CD34 + /CD38 − cells were determined using compensation quadrants generated by CD34 and CD38 dual-stained KGHarvested mononuclear cells from each (or each pair of two in the case of overnight storage; see below) leukopheresis 1A control cells. therapy (day 0). All patients received rhG-CSF 10 g/kg 3 months thereafter.
339
chemotherapy regimens. The data on the HD and NHL Supportive care
patients treated with an identical high-dose chemotherapy All patients received multilumen, indwelling central venous regimen but transplanted with unenriched PBPCs were used pheresis catheters and were cared for in single hospital to determine the expected engraftment outcome in our rooms. Antibiotics were given prophylactically or empiriinstitution. cally for fever and neutropenia according to the guidelines of each participating institution, and all patients were supPositive selection and in vitro characterization of ported with irradiated blood components. Irradiated, packed peripheral blood CD34 + cells RBC transfusions were given in an attempt to keep the Hct Ͼ25%, and irradiated platelet transfusions were given for
In the study group use of cyclophosphamide, prednisone platelet counts less than 10-20 × 10 9 /l or bleeding compliand rhG-CSF resulted in collection of 13.0 × 10 8 monocations. CMV-negative blood products were given to nuclear cells/kg during a mean 2.8 ± 1 leukophereses pro-CMV-seronegative patients. Toxicity grading was cedures (Table 2 ). CD34 + cell concentration of the starting accomplished using the common toxicity criteria (CTC) of MNC pool was 1.5% ± 1.8 and increased to 48% ± 31 folthe National Cancer Institute.
lowing column separation. In a total of 41 column separations the average recovery (yield) of CD34 + cells was 58% with 133-fold enrichment. Total CFU recovery (CFUStatistics GM + CFU-GEMM + BFU-E) was somewhat lower than the CD34 + cell yield, 37% with a 29-fold enrichment. /l for 7 consecutive days without transfusion at a median of cal study based on the availability of the technique (one study patient per week). Majority of the patients had refrac-15 days (range 9-39 days). This rapid engraftment was equivalent to patients who were treated with an identical tory and advanced stage disease and received two prior PBPC = peripheral blood progenitor cell; MNC = mononuclear cell; CFU = colony-forming unit; ANC = absolute neutrophil count; Plt = platelet count. a n = 22 patients for CFU/CD34 + cell data.
preparative regimen and re-infused with unenriched hand, CD34 + cell percentage and CFU concentration was 2.2-and 2.1-fold less in enriched cells processed after overPBPCs (Table 2) .
night storage (P = 0.0001 and 0.04, respectively). As a result, use of overnight storage led to infusion of a mean Effect of the overnight storage procedure on enrichment 2.6-fold less CD34 + cells to these patients (5 × 10 6 /kg vs procedure and hematopoietic engraftment 12.8 × 10 6 /kg). Although ANC recovery was not different In order to optimize immunoaffinity column utilization and between groups, patients who received cells processed after decrease cell processing labor, we employed the overnight overnight storage had significantly prolonged platelet storage technique for 36 pheresis products from 11 patients engraftment time, 28.5 days (12-39 days) compared to using 19 immunoaffinity columns. After combining the patients who received freshly processed cells, 13 days (9-overnight stored cell collection with the one collected the 19 days) (Table 3 ). This delay in platelet count recovery same day a median of 14.7 ± 5.2 × 10 8 MNCs/kg containing was observed even in patients who received more than 1.1 ± 1.7% CD34 + cells were processed. The starting mono-2.0 × 10 6 /kg CD34 + cells (Figure 1 ). Delayed platelet count nuclear cell or target CD34 + cell numbers were not signifirecovery (over 21 days) was observed in three out of five cantly different than in the group of patients whose collecpatients who received у2.0 × 10 6 /kg CD34 + cells after tions were not stored overnight (Table 3) . On the other overnight storage, compared to 0 out of eight patients who MNC = mononuclear cell; CFU = colony-forming unit; ANC = absolute neutrophil count; Plt = platelet count; NS = not significant.
there are several observations that indirectly implicate contaminating tumor cells contributing to relapse in patients with lymphoma. 11, 32 Clinical efficacy of purging has been difficult to elucidate in leukemias and lymphomas due to the positive relationship between the patient's tumor burden and the degree of tumor contamination in the hematopoietic cell harvest and the biologic differences of tumor cell susceptibility to purging agents.
14 Nevertheless, purging of autologous grafts for lymphoma is actively pursued since more than 50% of the patients with relapsed lymphoma will eventually die of their disease. In order to improve the outcome of the relapsed lymphoma patients and study the role of purging in overall outcome, it is important to develop effective and relatively simple means of tumor cell purging for PBPC collections with preservation of rapid engraftment capacity.
We report successful use of autologous CD34 + enriched peripheral blood mononuclear cells for hematopoietic reconstitution following myeloablative chemotherapy in lections. The automated CD34 + enrichment procedure was not labor-intensive and could be completed within 3-4 h. The volume of cells in the cryopreserved infusate was only received у2.0 × 10 6 /kg CD34 + cells without overnight storage (P = 0.035 Fisher's exact test).
5-10 ml. Time to neutrophil and platelet engraftment after reinfusion with CD34 + cell-enriched PBPCs was equivalent to that observed in the group of patients who received unenPatient outcome and tumor responses riched autologous PBPCs. The total number of CD34 + cells required for successful engraftment of the patient was colThere was one early death (day +10 after high-dose chemotherapy and re-infusion of CD34 + cells) due to sepsis, lected in 1-4 leukopheresis procedures despite recovery of a mean of 58% of the CD34 + cells following immunoaffinamong the 21 study patients. The remaining 20 patients were analyzed for tumor response on day +42. Fourteen ity column treatment.
34,35
Gorin et al 20 previously reported successful engraftment patients attained complete and four patients attained partial clinical remission with the high-dose chemotherapy regiwith purified CD34 + cells obtained from the BM of 25 patients with NHL in complete remission. They used an men used and two patients demonstrated evidence of progressive disease. In a median follow-up of 17 months, overidentical CEPRATE SC immunoaffinity column, and CD34 + cell and CFU enrichment, and yields were similar all and progression-free survival after transplant were 68% and 50%, respectively. to our data. However, we observed faster neutrophil and platelet recovery with mobilized peripheral blood CD34
+ cells compared to the BM CD34 + cells reported by Gorin et al. This difference may be explained by the lower numDiscussion ber of CD34 + cells that can be recovered and enriched from steady-state bone marrow (mean: 1.1 × 10 6 /kg, range: 0.3-Outcome of the relapsed lymphoma patient has improved significantly with high-dose chemotherapy and reconsti-2.96) 20 compared to mobilized peripheral blood in this study (mean: 8.7 × 10 6 /kg range: 0.3-25.7). There also may tution of hematopoiesis by stem cell transplantation. Mobilized PBPCs have dramatically lowered the morbidity and be differences in the cell cycle status of CD34 + cells obtained from these two sources. Negrin et al 12 using a cost of such therapy due to significant reduction in engraftment time compared to conventional steady-state discontinuous Percoll gradient for enrichment and purging of PBPCs in patients with NHL, reported 4.2-fold enrichbone marrow harvests. [28] [29] [30] Although effective, there are problems associated with the use of autologous transplanment of CD34 + cells with 81% recovery. Rapid neutrophil and platelet engraftment was observed despite further ex tation in lymphoma patients. Various investigators have suggested that PBPC collections may contain fewer tumor vivo purging of these cells with anti-B or T cell monoclonal antibodies. These results compare favorably with other cells than bone marrow. 15 Tumor cells, however still appear to be present in PBPCs. 19 Gene marking studies in acute purging agents such as 4-hydroperoxycyclophosphamide and is less labor-intensive and not associated with myeloid leukemia and neuroblastoma provided the first direct evidence that tumor cells contaminating the autologdelayed engraftment.
14 The number of CD34 + cells/kg infused and prior ous grafts do contribute to relapse. 31 Although such direct evidence is lacking for lymphoma, exposure to alkylator therapy are known to correlate with the time that it takes for neutrophil and platelet count recovAcknowledgements ery. 33 appeared to have an independent negative impact on plate- currently ongoing.
